

INVESTOR WEBINAR PRESENTATION

Genetic Signatures Limited (ASX: GSS, “Genetic Signatures” or the “Company”) is pleased to announce its participation in the ShareCafe Small Cap “Hidden Gems” Webinar, to be held Friday 18th of February 2022 from 12:30pm AEDT / 9:30am AWST.

Chief Executive Officer Dr. John Melki will provide an overview of the development and commercialisation of the Company’s proprietary platform technology, **3base®**. The **3base®** platform provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens with a high degree of specificity in rapid time.

This webinar is able to be viewed live via Zoom and will provide viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies.

To access further details of the event and to register at no cost, please copy and paste the following link into your internet browser:

https://us02web.zoom.us/webinar/register/3216444590728/WN_xXhnUtOFRmKy99-5ik47TA

A recorded copy of the webinar will be made available following the event.

Announcement authorised by Genetic Signatures’ Board of Directors

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki

Chief Executive Officer

john.melki@geneticsignatures.com

T: +61 (0)2 9870 7580

Peter Manley

Chief Financial Officer

peter.manley@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures’ proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.